CHMP5 and infection: Although the B.1.351 spike protein has multiple mutations in key antigenic sites in the RBD and NTD [1,2], the neutralizing antibody response elicited by B.1.351 infection is at least as RBD-focused as for early 2020 infections, suggesting that none of the RBD mutations have reduced the antigenicity of that spike subdomain.